Alan L Epstein, MD, PhD

Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.

• Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma J Neurosurg. 2023 Dec 29; 1-9. . View in PubMed
• Immune Priming with Spatially Fractionated Radiation Therapy Curr Oncol Rep. 2023 Dec; 25(12):1483-1496. . View in PubMed
• Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies J Neurosurg. 2023 09 01; 139(3):822-830. . View in PubMed
• Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression Blood. 2022 06 02; 139(22):3290-3302. . View in PubMed
• Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression Biochem Biophys Res Commun. 2022 12 17; 634:100-107. . View in PubMed
• The anticancer effects of Metformin in the male germ tumor SEM-1 cell line are mediated by HMGA1 Front Endocrinol (Lausanne). 2022; 13:1051988. . View in PubMed
• Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes Mol Ther. 2022 09 07; 30(9):3066-3077. . View in PubMed
• Restoration of Follicular T Regulatory/Helper Cell Balance by OX40L-JAG1 Cotreatment Suppresses Lupus Nephritis in NZBWF1/j Mice J Immunol. 2022 06 01; 208(11):2467-2481. . View in PubMed
• Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives Int J Mol Sci. 2021 Jun 16; 22(12). . View in PubMed
• Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor through Activation of MMP-2 Cancers (Basel). 2021 Jan 08; 13(2). . View in PubMed
• NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment Mol Cancer Ther. 2021 12; 20(12):2384-2397. . View in PubMed
• Adopting an alternative structure for clinical trials in immunotherapy Expert Rev Anticancer Ther. 2021 04; 21(4):373-375. . View in PubMed
• Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma Haematologica. 2021 06 01; 106(6):1714-1724. . View in PubMed
• Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma Oncoimmunology. 2021 01 04; 10(1):1838140. . View in PubMed
• Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model Sci Rep. 2021 07 23; 11(1):15077. . View in PubMed
• Neuro Oncol. 2021 01 30; 23(1):63-75. . View in PubMed
• Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19 Cureus. 2020 Sep 14; 12(9):e10447. . View in PubMed
• Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations Antibodies (Basel). 2020 Jun 10; 9(2). . View in PubMed
• Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma Biomaterials. 2020 12; 262:120338. . View in PubMed
• Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract Leukemia. 2020 05; 34(5):1467-1471. . View in PubMed
• Comparative Analysis of Cytokines of Tumor Cell Lines, Malignant and Benign Effusions Around Breast Implants Aesthet Surg J. 2020 05 16; 40(6):630-637. . View in PubMed
• A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models Clin Cancer Res. 2020 07 15; 26(14):3694-3706. . View in PubMed
• Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy Mol Ther. 2020 02 05; 28(2):536-547. . View in PubMed
• Expression of the luteinizing hormone receptor (LHR) in ovarian cancer BMC Cancer. 2019 Nov 15; 19(1):1114. . View in PubMed
• Antibodies to Brewer’s Yeast in Rheumatoid Arthritis Cureus. 2019 May 17; 11(5):e4691. . View in PubMed
• Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation Cell Mol Immunol. 2019 02; 16(2):138-153. . View in PubMed
• Generation of a Monoclonal Antibody to Detect Elastin-like Polypeptides Biomacromolecules. 2019 08 12; 20(8):2942-2952. . View in PubMed
• OX40L-JAG1-Induced Expansion of Lineage-Stable Regulatory T Cells Involves Noncanonical NF-? B Signaling. J Immunol. 2019 12 15; 203(12):3225-3236.. View in PubMed
• Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes Nat Commun. 2019 02 12; 10(1):713. . View in PubMed
• IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis Hum Pathol. 2018 08; 78:54-62. . View in PubMed
• Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models Nat Commun. 2018 05 22; 9(1):2024. . View in PubMed
• Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma Int J Mol Sci. 2017 Dec 20; 18(12). . View in PubMed
• Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations Proc Natl Acad Sci U S A. 2017 04 11; 114(15):3975-3980. . View in PubMed
• Sci Rep. 2017 07 26; 7(1):6594. . View in PubMed
• Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling Sci Rep. 2017 01 03; 7:39751. . View in PubMed
• Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma Aesthet Surg J. 2016 Jul; 36(7):773-81. . View in PubMed
• Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models Cancer Immunol Immunother. 2016 May; 65(5):511-23. . View in PubMed
• Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent Thyroid. 2016 Mar; 26(3):381-9. . View in PubMed
• Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice Autoimmunity. 2016 08; 49(5):298-311. . View in PubMed
• Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant J Immunother Cancer. 2016; 4:11. . View in PubMed
• Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins J Immunol Res. 2016; 2016:2342187. . View in PubMed
• Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases Plast Reconstr Surg. 2015 Mar; 135(3):695-705. . View in PubMed
• Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies J Cancer Sci Ther. 2015; 7(6):167-174. . View in PubMed
• MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. . View in PubMed
• Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. . View in PubMed
• BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration Thyroid. 2014 Sep; 24(9):1385-93. . View in PubMed
• Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model Appl Radiat Isot. 2014 Jun; 88:59-63. . View in PubMed
• A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody ACS Nano. 2014 Mar 25; 8(3):2064-76. . View in PubMed
• CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma J Immunol. 2014 Jan 01; 192(1):224-33. . View in PubMed
• Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models Mol Cancer Ther. 2013 Dec; 12(12):2827-36. . View in PubMed
• Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy J Immunother. 2013 Nov-Dec; 36(9):477-89. . View in PubMed
• Modulation of Treg cells/T effector function by GITR signaling is context-dependent Eur J Immunol. 2013 Sep; 43(9):2421-9. . View in PubMed
• Generation of tumor-targeted antibody-CpG conjugates J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. . View in PubMed
• Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma Head Neck Oncol. 2013 Feb 27; 5(3):24. . View in PubMed
• Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1Urology. 2013 Feb; 81(2):464. e1-9. . View in PubMed
• An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas Clin Cancer Res. 2012 Sep 01; 18(17):4657-68. . View in PubMed
• Survival signals and targets for therapy in breast implant-associated ALK–anaplastic large cell lymphoma Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. . View in PubMed
• The perichromatin region of the plant cell nucleus is the area with the strongest co-localisation of snRNA and SR proteins Planta. 2012 Aug; 236(2):715-26. . View in PubMed
• Unique approach for B lymphoma therapy Blood. 2012 Apr 19; 119(16):3647-8. . View in PubMed
• Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators J Clin Cell Immunol. 2012; Suppl 5:004. . View in PubMed
• A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome Case Rep Gastrointest Med. 2012; 2012:164305. . View in PubMed
• Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies Appl Radiat Isot. 2011 Dec; 69(12):1713-6. . View in PubMed
• Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors Immunotherapy. 2011 Nov; 3(11):1317-40. . View in PubMed
• USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics Oral Oncol. 2011 Sep; 47(9):810-7. . View in PubMed
• Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines J Transl Med. 2011 Jun 09; 9:90. . View in PubMed
• A new mechanism for blocking myeloid-derived suppressor cells by CpG Clin Cancer Res. 2011 Apr 01; 17(7):1645-8. . View in PubMed
• Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity Cancer. 2011 Apr 01; 117(7):1478-89. . View in PubMed
• Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab J Rheumatol. 2011 Feb; 38(2):398-9. . View in PubMed
• A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment Cancer Res. 2010 Nov 15; 70(22):9041-52. . View in PubMed
• Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells J Immunol. 2010 Aug 15; 185(4):2273-84. . View in PubMed
• Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1 Head Neck Oncol. 2010 Feb 22; 2:5. . View in PubMed
• Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity J Immunol. 2009 May 01; 182(9):5430-8. . View in PubMed
• Influence of an educational seminar on use of disease activity measurements by rheumatologists in treatment of rheumatoid arthritis J Rheumatol. 2009 Mar; 36(3):532-8. . View in PubMed
• Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients Cancer Immunol Immunother. 2008 May; 57(5):677-84. . View in PubMed
• Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother. 2008 Apr; 31(3):235-45. . View in PubMed
• Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer Clin Cancer Res. 2008 Jan 15; 14(2):579-88. . View in PubMed
• Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. . View in PubMed
• RA8, a human anti-CD25 antibody against human Treg cells Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. . View in PubMed
• Lym-1-induced apoptosis of non-Hodgkin’s lymphomas produces regression of transplanted tumors Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. . View in PubMed
• Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines Leuk Lymphoma. 2007 May; 48(5):944-56. . View in PubMed
• Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors Clin Cancer Res. 2007 May 01; 13(9):2758-67. . View in PubMed
• Soluble Fc fusion proteins for biomedical research Methods Mol Biol. 2007; 378:33-52. . View in PubMed
• B71/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. . View in PubMed
• H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models J Immunother. 2006 May-Jun; 29(3):274-83. . View in PubMed
• 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. . View in PubMed
• Combination B7-Fc fusion protein treatment and Treg cell depletion therapy Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. . View in PubMed
• Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin’s lymphomas Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. . View in PubMed
• NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. . View in PubMed
• Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer J Clin Oncol. 2005 Mar 01; 23(7):1538-47. . View in PubMed
• chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors Hybrid Hybridomics. 2004 Feb; 23(1):1-10. . View in PubMed
• Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G J Leukoc Biol. 2004 Jan; 75(1):99-105. . View in PubMed
• Tumor targeting properties of indium-111 labeled genetically engineered Fab’ and F(ab’)2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. . View in PubMed
• Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion Cancer Res. 2003 Dec 01; 63(23):8384-92. . View in PubMed
• Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis Cancer Res. 2003 Aug 15; 63(16):5046-53. . View in PubMed
• Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies Hybrid Hybridomics. 2003 Aug; 22(4):197-207. . View in PubMed
• LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors J Immunother. 2003 Jul-Aug; 26(4):320-31. . View in PubMed
• Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood. 2003 Jun 15; 101(12):4853-61. . View in PubMed
• Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT) Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. . View in PubMed
• Identification of a protein fragment of interleukin 2 responsible for vasopermeability J Natl Cancer Inst. 2003 May 21; 95(10):741-9. . View in PubMed
• Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors Hybrid Hybridomics. 2003 Feb; 22(1):1-9. . View in PubMed
• Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins Hybrid Hybridomics. 2002 Dec; 21(6):421-32. . View in PubMed
• Stable, genetically engineered F(ab’)(2) fragments of chimeric TNT-3 expressed in mammalian cells Hybrid Hybridomics. 2002 Feb; 21(1):11-8. . View in PubMed

• Lenz, Heinz-Josef
• Kast, Wijbe